

## Preliminary Programme

### Thursday, 9 October

#### 12:55-14:25

#### Transplant 1: HLA and donor selection

*Moderators: Annalisa Ruggeri (IT) and Frederic Baron (FR)*

12:55-13:05

Graft composition and impact on transplantation platforms

Jurgen Kuball (NL)

13:05-13:20

CB expansion

Guy Sauvageau (CA)

13:20-13:35

HLA

13:35-13:50

Algorithm for donor selection

Mohamad Mohty (FR)

13:50-14:25

Panel discussion: All session faculty

#### 14:35-16:05

#### Transplant 2: Graft-versus-Host disease

*Moderators: Federico Simonetta (IT) and Bipin Savani (US)*

14:35-14:50

PTCy tolerance and long term effect

Annalisa Ruggeri (IT)

14:50-15:05

T cell depletion or no T cell depletion?

Moniek de Witte (NL)

15:05-15:20

Immunomonitoring after HCT and CAR T

Simona Pagliuca (FR)

15:20-15:35

New treatment for a and cGVHD

Florent Malard (FR)

15:35-16:05

Panel discussion: All session faculty

### Friday, 10 October

#### 08:15-09:45

#### Transplant 3: ALL management

*Moderators: Florent Malard (FR)*

08:15-08:30

Does addition of Blinatumomab change the role of allo HCT in first line ALL treatment?

08:30-08:45

Does Remission after CAR T treatment replace allo SCT?

Eolia Brissot (FR)

08:45-09:00

CAR T cell in T-ALL

Ana Alarcon (ES)

09:00-09:15

Why does age still play a major role in access to CAR T in ALL?

09:15-09:45

Panel discussion: All session faculty

#### 11:40-13:10

#### Transplant 4: AML management

*Moderators: Zinaida Peric (HR) and Didier Blaise (FR)*

11:30-11:45

Predictive score for AML

Alexandros Spyridonidis (GR)

11:45-12:00

Conditioning regimen in AML

Raynier Devillier (FR)

12:00-12:15

Maintenance in AML

Ali Bazarbachi (LB)

12:15-12:30

CAR T construct for AML

12:30-13:00

Panel discussion: All session faculty

#### 15:30-17:30

#### ALWP Scientific Business meeting

#### 15:30-17:30

#### CTIWP Scientific Business meeting

#### 17:30-18:30

#### Joint Scientific Business meeting

### Saturday, 11 October

#### 08:15-09:45

#### Transplant 5: Management of relapse of AML and ALL after alloHCT

*Moderators: Jurgen Kuball (NL) and Fabio Ciceri (IT)*

08:15-08:30

Biology of leukemia relapse

Giorgio Orofino (IT)

08:30-08:45

Clinical case nurses

Annalisa Ruggeri (IT)

08:45-09:00

Treatment of relapse

09:00-09:15

Application of DLI

Nicole Santoro (IT)

09:15-09:45

Panel discussion: All session faculty